Evozyne Raises $81M in Series B Financing


Evozyne, a Chicago, IL-based Generative AI company focused on therapeutic discovery and drug development, closed an $81m Series B funding round.

The round was led by Fidelity Management & Research Company and OrbiMed with participation from NVentures, NVIDIA’s venture capital arm, as well as previous investors Paragon Biosciences and Valor Equity Partners.

The company intends to use the funds to advance its generative AI-powered drug discovery platform and product development.

Founded in 2020 and led by Mike Gamson, CEO, Evozyne has collaborated with NVIDIA earlier this year to develop an AI model that can be used to design therapeutic proteins. The approach aims to exponentially increase the number and quality of synthetic protein designs, which opens up the possibility to design new therapeutics and reduce development time for new treatments.